Conditions

Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.

Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.

Patients projected to have increase in body mass index also likely to develop increased plasma glucose levels and have diminished insulin response.

Young man, 21 years of age. type 1 diabetes since 9 years of age. Has not been to see hcp for a year. States he doesn’t like people interrogating him, but came in because he needs his insulin. States he doesn’t check his glucose because he can tell what it is. Tired of having type 1 diabetes and tired of checking numbers. A1C in office--10.2%.

The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.

Young patients with low BMIs, C-peptide levels, and significant symptoms at onset of diabetes at higher risk of undergoing rapid C-peptide decline.

Patients are not seeing the expected results because of medication adherence.

Getting type 2 diabetes at an early age increases risk for all diabetes complications, including death.

How best to decide whether to use one or a combination of the new treatments and individualize the treatment for your patients.

With much of the U.S. in the grip of harsh winter weather as December 2017 comes to a close, we're revisiting a post we originally published in 2013 about how having diabetes or prediabetes can increase the risk of frostbite. The risk was dramatically illustrated by the experience of British explorer Sir Ranulph Fiennes, who had to pull out of a grueling expedition to cross Antarctica due to the effects of frostbite. We wish all our readers a healthy, safe, and warm new year!